Pacanalotamab Biosimilar - Anti-TNFRSF17;CD3E mAb - Research Grade
Source
CAS 2251756-52-0
Species
Humanized
Expression system
XtenCHO
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Delivery Time
3-5 days if in stock; 3 week if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Pacanalotamab,AMG420,BISPECIFIC T-CELL ENGAGER ANTIBODY WITH A SINGLE CHAIN FC MOIETY THAT BINDS TO B CELL MATURATION, ANTIGEN SURFACE RECEPTOR AND CD3, AMG-420, BI-836909,TNFRSF17;CD3E,anti-TNFRSF17;CD3E
Reference
PX-TA1698
Note
For research use only. Not suitable for human use.
Isotype
Bispecific scFv,Kappa;Lambda
Clonality
Monoclonal Antibody
Description of Pacanalotamab Biosimilar - Anti-TNFRSF17;CD3E mAb - Research Grade
Introduction
Pacanalotamab Biosimilar, also known as Anti-TNFRSF17,CD3E mAb, is a novel therapeutic antibody that targets TNFRSF17, also known as BCMA (B-cell maturation antigen), and CD3E, a component of the T-cell receptor complex. This biosimilar is currently in the research grade stage and has shown promising results in pre-clinical studies. In this article, we will discuss the structure, activity, and potential applications of Pacanalotamab Biosimilar.
Structure of Pacanalotamab Biosimilar
Pacanalotamab Biosimilar is a monoclonal antibody (mAb) that is produced through recombinant DNA technology. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for binding to the target molecules, TNFRSF17 and CD3E, while the constant regions provide stability and effector functions.
The amino acid sequence of Pacanalotamab Biosimilar is highly similar to the reference product, making it a biosimilar. This means that it has comparable structure, function, and efficacy to the reference product, but may have minor differences in its composition.
Activity of Pacanalotamab Biosimilar
The main mechanism of action of Pacanalotamab Biosimilar is through binding to TNFRSF17 and CD3E. TNFRSF17 is a cell surface receptor that is highly expressed on malignant plasma cells, making it a potential therapeutic target for multiple myeloma and other B-cell malignancies. By binding to TNFRSF17, Pacanalotamab Biosimilar can block its signaling pathway, leading to inhibition of cell growth and survival.
In addition, Pacanalotamab Biosimilar also binds to CD3E, which is expressed on T-cells. This results in the formation of a complex between the antibody, TNFRSF17, and CD3E, leading to the activation and proliferation of T-cells. This dual mechanism of action makes Pacanalotamab Biosimilar a potential immunotherapeutic agent for the treatment of B-cell malignancies.
Applications of Pacanalotamab Biosimilar
As mentioned earlier, Pacanalotamab Biosimilar has shown promising results in pre-clinical studies for the treatment of multiple myeloma and other B-cell malignancies. It has the potential to be used as a monotherapy or in combination with other anti- cancer agents.
In addition, Pacanalotamab Biosimilar may also have applications in autoimmune diseases, as TNFRSF17 has been implicated in the pathogenesis of certain autoimmune disorders. By targeting TNFRSF17, Pacanalotamab Biosimilar can potentially modulate the immune response and provide therapeutic benefits for these conditions.
Conclusion
Pacanalotamab Biosimilar is a promising therapeutic antibody that targets TNFRSF17 and CD3E. Its structure and activity make it a potential treatment option for multiple myeloma, other B-cell malignancies, and autoimmune diseases. As it progresses through clinical trials, Pacanalotamab Biosimilar has the potential to provide a new and effective treatment for patients with these conditions.
Reviews
There are no reviews yet.